Gevokizumab Completed Phase 2 Trials for Pyoderma Gangrenosum Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01882504Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum